GSK Pharma's total revenues increased by 13% YoY to Rs 7356 mn in Q3FY16 lower than our estimates of Rs 7513 mn. Operating margins decreased by 270bps YoY to 14.9% (lower than our estimate of 17.7%) on account of lower gross margins and CSR exps of Rs 136.7 mn.